OSR | 10-Q: FY2025 Q3 Revenue: USD 627.75 K

Revenue: As of FY2025 Q3, the actual value is USD 627.75 K.

EPS: As of FY2025 Q3, the actual value is USD -0.1.

EBIT: As of FY2025 Q3, the actual value is USD -3.778 M.

Net Sales: For the three months ended September 30, 2025, net sales were $627,747, a decrease of $195,249 or 24% compared to the same period in 2024. For the nine months ended September 30, 2025, net sales were $2,524,536, a decrease of $90,515 or 3% compared to the same period in 2024.

Gross Profit: For the three months ended September 30, 2025, gross profit was $261,734, an increase of $82,641 or 46% compared to the same period in 2024. For the nine months ended September 30, 2025, gross profit was $463,201, a decrease of $188,014 or 29% compared to the same period in 2024.
Operating Loss: For the three months ended September 30, 2025, operating loss was $3,803,465, an increase of $236,923 or 7% compared to the same period in 2024. For the nine months ended September 30, 2025, operating loss was $11,950,469, an increase of $1,871,291 or 19% compared to the same period in 2024.
Net Loss: For the three months ended September 30, 2025, net loss was $3,194,874, a decrease of $161,659 or 5% compared to the same period in 2024. For the nine months ended September 30, 2025, net loss was $19,812,886, an increase of $10,823,499 or 120% compared to the same period in 2024.

Operating Cash Flow: For the nine months ended September 30, 2025, net cash used in operating activities was $3,258,041, an increase of $1,589,597 or 95% compared to the same period in 2024.
Free Cash Flow: Not explicitly mentioned, but can be inferred from operating cash flow and capital expenditures.

Merger-Related Expenses: Approximately $8.5 million in merger-related expenses were recognized in connection with the Business Combination completed on February 14, 2025.

Revenue Model Transition: RMC transitioned from a traditional purchase-and-resale model to a consignment-based arrangement, which is expected to enhance gross-margin stability in future periods.
R&D Expenses: OSR Holdings expects to incur and report R&D related expenses mainly from its subsidiaries actively engaged in R&D at an estimated amount of $2.5 million to $3.0 million per quarter beginning in 2026, potentially increasing to $5.0 million to $6.0 million per quarter.

Equity Line of Credit (ELOC): OSR Holdings entered into an ELOC agreement providing for up to $80 million in potential capital. As of September 30, 2025, the Company had issued a total of 767,500 shares under the ELOC, raising gross proceeds of $741,937.
Convertible Bonds: The Company has a convertible note agreement with White Lion Capital, with an outstanding balance of $256,959 as of September 30, 2025.

Nasdaq Compliance: The Company received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement. Management is actively monitoring the share price and evaluating options to regain compliance, including potential corporate or capital structure adjustments.
Strategic Acquisition: OSR Holdings announced a definitive share exchange agreement with Woori IO Co., Ltd., a Korean medical-device company, to become a wholly owned subsidiary. This acquisition aims to leverage OSRH’s governance, global partnerships, and clinical development resources to accelerate product development and commercialization.